Navigation Links
MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
Date:11/7/2007

acquire the intellectual property rights relating to the Company's cephalexin PULSYS business, or $11.0 million if Deerfield has not acquired these rights (in each case subject to certain adjustments), assuming the Company exercises its repurchase rights prior to November 7, 2008. Those repurchase prices will increase by $2.0 million on each subsequent anniversary of that date. The Company's exercise of this purchase right is mandatory upon the change of control of the Company.

About Middlebrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK, formerly Advancis Pharmaceutical Corporation) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing a portfolio of anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front-loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). By examining the resistance patterns of bacteria and applying its delivery technologies, MiddleBrook has the potential to redefine infectious disease therapy and significantly improve drug efficacy, shorten length of therapy, and reduce drug resistance versus currently available antibacterial products. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

About Keflex:

Keflex(R) (cephalexin capsules, USP) is a third-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram- negative aerobes in vitro and in clinical infections. Keflex is indicated for treatment of the following infections: respiratory tract infections, otitis media, skin and
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... (Providence, RI)--- EpiVax, Inc, a leader in the field ... funding from the Juvenile Diabetes Research Foundation (JDRF), the ... to develop Epi-13, a novel therapeutic for the prevention ... chronic autoimmune disease that affects up to three million ...
... 2007 - Diseases that cause neurons to break-down, ... (Mad Cow Disease), continue to be elusive to ... from University of Michigan researchers demonstrates an unpredicted ... neuron health., In a study released in PNAS, ...
... ElBaradei will join more than 100 leading public figures, ... in New York on 29 October to mark the ... the US based National Foundation for Cancer Research (NFCR). ... PACT Fund at NFCR, Americans can support the IAEA ...
... is generally considered to be safe with a low ... tube can lead to serious complications. , The ... Dr. Imamura of Aichi Medical University Hospital. It was ... Gastroenterology. , An 86-year-old woman with gastrostomy tube feeding ...
... ALTO, Calif., Oct. 25 ASTRO Booth # ... today announced that it has developed,groundbreaking technology for ... of volumetric arc therapy. Varian,s new RapidArc(TM),radiotherapy technology* ... to deliver more precise forms of intensity-modulated radiation,therapy ...
... Coley,Pharmaceutical Group, Inc. (Nasdaq: COLY ), today announced ... 4:30 p.m. Eastern Time on November,1, 2007 to discuss ... live audio broadcast or the subsequent archived recording,of the ... Coley website,at http://www.coleypharma.com . Please log onto Coley,s ...
Cached Medicine News:Health News:EpiVax receives JDRF program funding to develop diabetes drug using natural 'regulatory' T-cells 2Health News:U-M scientists find new causes for neurodegeneration 2Health News:IAEA and NFCR join forces to fight cancer in developing world 2Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 2Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 3Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 4Health News:Coley Pharmaceutical Group to Report Third Quarter Results on November 1, 2007 2
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... , BOCA RATON, Fla., Nov. 18 Lexington Intl, manufacturer ... 14 leading manufacturing exporting companies nationwide to receive the President,s ... contributions to the U.S. economy. , Presented to Lexington at ... U.S. Secretary of Commerce, Gary Locke and Florida Senator George ...
... Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ) has ... approval from the US Food and Drug Administration (FDA). ... of hypertension when oral therapy is not feasible or ... 25 mg/10ml single use ampuls containing 2.5 mg/ml of ...
Cached Medicine Technology:Lexington International, LLC Receives 2009 U.S. President's 'E' Award Recognizing its Export Achievements 2Lexington International, LLC Receives 2009 U.S. President's 'E' Award Recognizing its Export Achievements 3Caraco Pharmaceutical Laboratories, Ltd. Markets Nicardipine Hydrochloride Injection 2
... Card is specially designed to be a corrected ... Rosenbaum card (as noted by Horton and Jones ... "J" notations are not used because of the ... the Wormington NP Card, the examiner can measure ...
Standard reading test. 'It was the month of May'...
Standard reading test. "Children should be..."...
Printed with large 20/200 E on one side and a series of five 20/20 tumbling Es on the other- calibrated to a 20 ft. distance. May be used to test and train peripheral awareness....
Medicine Products: